Literature DB >> 3408648

Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.

M J Harding1, B M Cantwell, R A Milstead, A L Harris, S B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3408648      PMCID： PMC2246458          DOI： 10.1038/bjc.1988.143

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

Authors:  T R Jones; A H Calvert; A L Jackman; S J Brown; M Jones; K R Harrap
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

2.  Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.

Authors:  C Benz; E Cadman
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

3.  A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.

Authors:  A H Calvert; D L Alison; S J Harland; B A Robinson; A L Jackman; T R Jones; D R Newell; Z H Siddik; E Wiltshaw; T J McElwain
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

4.  A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.

Authors:  T R Buroker; C G Moertel; T R Fleming; L K Everson; S A Cullinan; J E Krook; J A Mailliard; R F Marschke; D J Klaassen; J A Laurie
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544
  4 in total
  5 in total

Review 1.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.

Authors:  B Mitrovski; J Pressacco; S Mandelbaum; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

4.  The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).

Authors:  B M Cantwell; A L Harris
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

5.  Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.